A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, albeit with a high incidence of hematologic toxicity and infections. The ...

Atezolizumab showed modest response rates in NSCLC patients previously treated with PD-1 inhibitors, with a suggested baseline response rate of 10% for new ICI combinations. The study's primary ...

Cretostimogene shows promising efficacy in bladder cancer treatment, with 75.5% complete response rate and sustained duration of over 28 months. CG Oncology, Inc. announced encouraging results from ...

Role of induction chemotherapy in locally advanced oropharyngeal carcinoma in Indian population. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a ...

Administrators should give instructors and students clear, visible examples of how course evaluation data has been used to improve the unit's programs, teaching and facilities. Instructors can ...

Zongertinib shows a 71% response rate and 12.4 months median progression-free survival in HER2-mutated NSCLC, with minimal adverse events. Patient-reported outcomes indicate rapid improvement in ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

Xilio Therapeutics reports 26% response rate for vilastobart and atezolizumab in metastatic MSS CRC patients, with favorable safety profile. Xilio Therapeutics has reported promising results from its ...

In a paper initially prepared for the planning meeting for this review, Peytchev (2013) observes that drawing “unbiased inference from probability-based surveys relies on the collection of data from ...